3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Renal Cell
6
Melanoma
4
Prostatic Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Kidney Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Upper Tract Urothelial Carcinoma
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Magnetic Resonance Spectroscopy
4
pembrolizumab
3
Trastuzumab
3
Sunitinib
3
Nivolumab
3
ulixertinib
2
tipifarnib
2
palbociclib
2
lenvatinib
2
belinostat
2
Specimen Handling
2
Sirolimus
2
Radiosurgery
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
spartalizumab
1
sargramostim
1
sapanisertib
1
romidepsin
1
relatlimab
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Immunotherapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled